JP7423097B2 - 循環腫瘍細胞を体外で拡大する方法及びキット、複合材料フィルム、その製造方法、薬物検査法、並びに凍結保存液 - Google Patents
循環腫瘍細胞を体外で拡大する方法及びキット、複合材料フィルム、その製造方法、薬物検査法、並びに凍結保存液 Download PDFInfo
- Publication number
- JP7423097B2 JP7423097B2 JP2022507398A JP2022507398A JP7423097B2 JP 7423097 B2 JP7423097 B2 JP 7423097B2 JP 2022507398 A JP2022507398 A JP 2022507398A JP 2022507398 A JP2022507398 A JP 2022507398A JP 7423097 B2 JP7423097 B2 JP 7423097B2
- Authority
- JP
- Japan
- Prior art keywords
- particles
- tumor cells
- circulating tumor
- vitro
- expanding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 title claims description 103
- 239000002131 composite material Substances 0.000 title claims description 59
- 238000000034 method Methods 0.000 title claims description 54
- 238000000338 in vitro Methods 0.000 title claims description 39
- 238000005138 cryopreservation Methods 0.000 title claims description 11
- 238000003255 drug test Methods 0.000 title 1
- 239000002245 particle Substances 0.000 claims description 135
- 239000000463 material Substances 0.000 claims description 47
- 210000004027 cell Anatomy 0.000 claims description 44
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 42
- 239000007788 liquid Substances 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 239000001963 growth medium Substances 0.000 claims description 19
- 239000000758 substrate Substances 0.000 claims description 18
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 16
- 239000012530 fluid Substances 0.000 claims description 15
- 239000002609 medium Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 229910052814 silicon oxide Inorganic materials 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 229910044991 metal oxide Inorganic materials 0.000 claims description 13
- 150000004706 metal oxides Chemical class 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 13
- 239000002923 metal particle Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 11
- 229920000728 polyester Polymers 0.000 claims description 11
- -1 polydimethylsiloxane Polymers 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- 238000006116 polymerization reaction Methods 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 7
- 235000012239 silicon dioxide Nutrition 0.000 claims description 7
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000178 monomer Substances 0.000 claims description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 6
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000004793 Polystyrene Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000012670 alkaline solution Substances 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 4
- 238000009832 plasma treatment Methods 0.000 claims description 4
- 229920002223 polystyrene Polymers 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229920002379 silicone rubber Polymers 0.000 claims description 4
- 239000004945 silicone rubber Substances 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 claims description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 3
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 239000010931 gold Substances 0.000 claims description 3
- 150000003440 styrenes Chemical class 0.000 claims description 3
- 230000004083 survival effect Effects 0.000 claims description 3
- 239000010936 titanium Substances 0.000 claims description 3
- 239000004408 titanium dioxide Substances 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 229920002050 silicone resin Polymers 0.000 claims description 2
- 239000004332 silver Substances 0.000 claims description 2
- 229910052709 silver Inorganic materials 0.000 claims description 2
- 229910052719 titanium Inorganic materials 0.000 claims description 2
- 238000010586 diagram Methods 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 13
- 206010006187 Breast cancer Diseases 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 238000005498 polishing Methods 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 210000005266 circulating tumour cell Anatomy 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 5
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 229940126864 fibroblast growth factor Drugs 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- AFRBPRLOPBAGCM-UHFFFAOYSA-N n-[2-(1h-indol-4-yl)ethyl]-n-propylpropan-1-amine Chemical compound CCCN(CCC)CCC1=CC=CC2=C1C=CN2 AFRBPRLOPBAGCM-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003849 aromatic solvent Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229940005642 polystyrene sulfonic acid Drugs 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000010539 anionic addition polymerization reaction Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000010538 cationic polymerization reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0215—Disinfecting agents, e.g. antimicrobials for preserving living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/20—Small organic molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
- C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Oncology (AREA)
- Sustainable Development (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
そこで、本発明の実施例には循環腫瘍細胞を体外で拡大するための複合材料フィルム、循環腫瘍細胞を体外で拡大するための複合材料フィルムの製造方法、循環腫瘍細胞を体外で拡大する方法、体外で循環腫瘍細胞を拡大するキット、薬物の効果を検査する方法、及び凍結保存液を開示し、循環腫瘍細胞を拡大する数量を有効的に増やす。
12 基材
20 混合液
22 粒子
24 溶剤
26 媒質材料
26' 誘電体層
30 細胞液
32 循環腫瘍細胞
32' 循環腫瘍細胞塊
34 培養液
100 方法
200 方法
201 液層
202 粒子層
203 複合材料フィルム
S102 ステップ
S104 ステップ
S106 ステップ
S108 ステップ
S202 ステップ
S204 ステップ
Claims (13)
- 金属粒子、金属酸化物粒子、酸化ケイ素粒子、及びそれらの組み合わせからなる群から選ばれる1種または複数種の粒子及び溶剤を混合して混合液を形成するステップと、
前記混合液を基材に載置し、粒子層を形成するステップと、
スチレン及びその派生物、ポリエステルモノマー、酸化ケイ素化合物、及びそれらの組み合わせからなる群から選ばれる媒質材料を前記粒子層に添加するステップと、
前記媒質材料に重合反応を発生させ、前記粒子層を前記基材に固定するように誘電体層を形成するステップと、を含むことを特徴とする循環腫瘍細胞を体外で拡大するための複合材料フィルムの製造方法。 - 前記金属粒子は、金粒子、銀粒子、チタン粒子、及びそれらの組み合わせからなる群から選ばれ、前記金属酸化物粒子は二酸化チタン粒子であり、前記酸化ケイ素粒子は二酸化ケイ素粒子(silicon dioxide particles)、シリカ粒子(silica particles)、ポリジ
メチルシロキサン粒子(polydimethylsiloxane particles)、及びそれらの組み合わせからなる群から選ばれることを特徴とする請求項1に記載の循環腫瘍細胞を体外で拡大するための複合材料フィルムの製造方法。 - 前記1種または複数種の粒子の粒径は10nm~10μmの間の範囲であることを特徴とする
請求項1に記載の循環腫瘍細胞を体外で拡大するための複合材料フィルムの製造方法。 - 表面プラズマ処理、親水性ポリマー塗布、酸またはアルカリ溶液ですすぐ、またはそれらの組み合わせを含む前記混合液を前記基材上に載置する前に前記基材に対し親水化前処理を施すステップを更に含むことを特徴とする請求項1に記載の循環腫瘍細胞を体外で拡大するための複合材料フィルムの製造方法。
- 前記混合液を前記基材に載置した後、載置処理を施し、前記混合液の前記1種または複数種の粒子を自己集合配列させ、前記粒子層を形成するステップを更に含むことを特徴とする請求項1に記載の循環腫瘍細胞を体外で拡大するための複合材料フィルムの製造方法。
- 前記載置処理を施した後、除湿乾燥、減圧乾燥、加熱乾燥、またはそれらの組み合わせを含む乾燥処理を行うステップを更に含むことを特徴とする請求項5に記載の循環腫瘍細胞を体外で拡大するための複合材料フィルムの製造方法。
- 前記スチレン派生物は、カルボキシル化スチレン(carboxylated styrene)、スチレンスルホン酸(styrene sulfonic acid)、またはそれらの組み合わせを含み、前記ポリエ
ステルモノマーはメタクリル酸メチル(methylmethacrylate)を含むことを特徴とする請求項1に記載の循環腫瘍細胞を体外で拡大するための複合材料フィルムの製造方法。 - 前記酸化ケイ素化合物は、ポリジメチルシロキサン(polydimethylsiloxane)、テトラエトキシシラン(tetraethoxysilane)、及びそれらの組み合わせからなる群から選ばれ
ることを特徴とする請求項1に記載の循環腫瘍細胞を体外で拡大するための複合材料フィルムの製造方法。 - 略規則的に配列されている1種または複数種の粒子を含み、前記1種または複数種の粒子は、金属粒子、金属酸化物粒子、酸化ケイ素粒子、及びそれらの組み合わせからなる群から選ばれる粒子層と、
前記粒子層の前記1種または複数種の粒子の間に介在し、ポリスチレン及びその派生物、ポリエステル、二酸化ケイ素、シリカゲル(silica gel)、シリコーン樹脂(silicone)、シリコーンゴム(silicone rubber)、及びそれらの組み合わせからなる群から選ばれ
る誘電体層と、を備え、
前記1種または複数種の粒子の部分的表面が前記誘電体層により被覆されずに露出することを特徴とする循環腫瘍細胞を体外で拡大するための複合材料フィルム。 - 循環腫瘍細胞を体外で拡大するためのキットであって、
培養容器と幹細胞培養液を含む培養液を備え、
前記培養容器は、
基材と、
前記基材に付着する請求項9に記載の複合材料フィルムと、を含むことを特徴とする循環腫瘍細胞を体外で拡大するためのキット。 - 複数の循環腫瘍細胞及び培養液を混合することにより、細胞液を形成するステップと、請求項1に記載の前記製造方法により製造した前記複合材料フィルムに前記細胞液を接触させ、これら前記循環腫瘍細胞を前記1種または複数種の粒子に付着すると共に拡大するステップと、を含むことを特徴とする循環腫瘍細胞を体外で拡大する方法。
- 請求項11に記載の方法で拡大した後のこれら前記循環腫瘍細胞に薬物を添加するステップと、
これら前記循環腫瘍細胞の生存率を検査するステップと、を含むことを特徴とする薬物の効果を検査する方法。 - 凍結保存液と請求項11に記載の方法により拡大された拡大後の循環腫瘍細胞とを混合して混合物を形成すること、および前記混合物を-70℃以下の温度で凍結保存することを含み、
前記凍結保存液は、冷凍試薬と、アルカリ性線維芽細胞成長因子(basic fibroblast growth factor、bFGF)及び上皮成長因子(epidermal growth factor、EGF)を有する培養液と、を含む、拡大後の循環腫瘍細胞を凍結保存するための方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962931236P | 2019-11-06 | 2019-11-06 | |
US62/931,236 | 2019-11-06 | ||
PCT/CN2020/126634 WO2021088902A1 (zh) | 2019-11-06 | 2020-11-05 | 体外扩增循环肿瘤细胞的方法、套组、复合材料薄膜及其制备方法、药物检测方法和冻存液 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022543433A JP2022543433A (ja) | 2022-10-12 |
JP7423097B2 true JP7423097B2 (ja) | 2024-01-29 |
Family
ID=75849741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022507398A Active JP7423097B2 (ja) | 2019-11-06 | 2020-11-05 | 循環腫瘍細胞を体外で拡大する方法及びキット、複合材料フィルム、その製造方法、薬物検査法、並びに凍結保存液 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220403328A1 (ja) |
JP (1) | JP7423097B2 (ja) |
TW (1) | TWI764359B (ja) |
WO (1) | WO2021088902A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003139A1 (en) | 1991-08-08 | 1993-02-18 | Kao Corporation | Cell culture support, production thereof, and production of cell cluster using same |
JP2010524494A (ja) | 2007-04-27 | 2010-07-22 | ヒュンジン ヤン | 比重の増加した細胞培養用支持体及びその製造方法 |
JP2015136318A (ja) | 2014-01-22 | 2015-07-30 | 国立大学法人 筑波大学 | 細胞培養用デバイス |
US20190300832A1 (en) | 2018-03-29 | 2019-10-03 | Taipei Medical University | Method and kit for expanding circulating tumor cells in vitro |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1871517A (zh) * | 2002-02-19 | 2006-11-29 | 免疫公司 | 快速有效分离循环癌细胞的方法和试剂 |
US20140154689A1 (en) * | 2012-12-05 | 2014-06-05 | Tim Hui-Ming Huang | Analysis of circulating tumor cells as diagnostic and predictive biomarkers for metastatic cancers |
US20160096967A1 (en) * | 2014-10-03 | 2016-04-07 | C3Nano Inc. | Property enhancing fillers for transparent coatings and transparent conductive films |
CN105043831A (zh) * | 2015-07-03 | 2015-11-11 | 石莹 | 一种俘获有核红细胞的纳米材料 |
CN108531455A (zh) * | 2018-03-09 | 2018-09-14 | 大连理工大学 | 用于循环肿瘤细胞捕获的多酚涂层 |
CN108872182A (zh) * | 2018-03-16 | 2018-11-23 | 广东医科大学 | 一种基于sers的循环肿瘤细胞检测方法 |
-
2020
- 2020-11-05 US US17/772,223 patent/US20220403328A1/en active Pending
- 2020-11-05 WO PCT/CN2020/126634 patent/WO2021088902A1/zh active Application Filing
- 2020-11-05 JP JP2022507398A patent/JP7423097B2/ja active Active
- 2020-11-05 TW TW109138515A patent/TWI764359B/zh active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003139A1 (en) | 1991-08-08 | 1993-02-18 | Kao Corporation | Cell culture support, production thereof, and production of cell cluster using same |
JP2010524494A (ja) | 2007-04-27 | 2010-07-22 | ヒュンジン ヤン | 比重の増加した細胞培養用支持体及びその製造方法 |
JP2015136318A (ja) | 2014-01-22 | 2015-07-30 | 国立大学法人 筑波大学 | 細胞培養用デバイス |
US20190300832A1 (en) | 2018-03-29 | 2019-10-03 | Taipei Medical University | Method and kit for expanding circulating tumor cells in vitro |
Also Published As
Publication number | Publication date |
---|---|
WO2021088902A1 (zh) | 2021-05-14 |
TW202118870A (zh) | 2021-05-16 |
JP2022543433A (ja) | 2022-10-12 |
US20220403328A1 (en) | 2022-12-22 |
TWI764359B (zh) | 2022-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yamada et al. | Cell-sized condensed collagen microparticles for preparing microengineered composite spheroids of primary hepatocytes | |
Cooperstein et al. | Biological cell detachment from poly (N-isopropyl acrylamide) and its applications | |
JP4567936B2 (ja) | 細胞培養用支持体材料、細胞の共培養方法およびそれより得られる共培養細胞シート | |
Bakirci et al. | Cell sheet based bioink for 3D bioprinting applications | |
WO2017177839A1 (zh) | 一种超疏水微坑阵列芯片及其制备方法与应用 | |
Liu et al. | A microfluidic chip with poly (ethylene glycol) hydrogel microarray on nanoporous alumina membrane for cell patterning and drug testing | |
US8557583B2 (en) | Cell culture support and manufacture thereof | |
US20200009567A1 (en) | Biocompatible Micropillar Array Substrate and Methods for Fabricating Such Substrate | |
CN105400735A (zh) | 用于培养干细胞衍生的心肌细胞的合成表面 | |
Tröndle et al. | Scalable fabrication of renal spheroids and nephron-like tubules by bioprinting and controlled self-assembly of epithelial cells | |
US8993322B2 (en) | Methods and kits for cell release | |
WO2016158039A1 (ja) | 医療器具、フッ素含有環状オレフィンポリマー、フッ素含有環状オレフィンポリマー組成物、および細胞培養方法 | |
JP7423097B2 (ja) | 循環腫瘍細胞を体外で拡大する方法及びキット、複合材料フィルム、その製造方法、薬物検査法、並びに凍結保存液 | |
Ma et al. | Thermomodulated cell culture/harvest in polydimethylsiloxane microchannels with poly (N-isopropylacrylamide)-grafted surface | |
US20230077412A1 (en) | 3d printed micro-millifluidic bioreactors for long-term retinal organoid maintenance | |
JP5098007B2 (ja) | 非スフェロイド化幹細胞の調製方法 | |
JP2013116130A (ja) | 細胞培養支持体とその製造方法 | |
WO2012162042A1 (en) | Methods of making and using polymers and compositions | |
JP7016150B2 (ja) | 細胞接着基材の作製方法 | |
Kung et al. | Microfluidic device‐assisted etching of p‐HEMA for cell or protein patterning | |
CN113248748A (zh) | 用于体外扩增循环肿瘤细胞的培养容器的复合材料薄膜的制备方法 | |
KR101856033B1 (ko) | 유도만능 줄기세포의 배양 용기 및 배양 방법 | |
Pannella et al. | Growth and neurotrophic factors in embryonic stem cells | |
JP7213487B2 (ja) | がん細胞の培養方法 | |
TW202317751A (zh) | 無血清培養液中之細胞培養用基底材料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220203 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230124 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230420 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230620 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230720 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230808 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231107 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240109 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240110 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7423097 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |